DS - Catapres

Download as doc, pdf, or txt
Download as doc, pdf, or txt
You are on page 1of 2

Drug Name CLONIDINE HYDROCHLORIDE Catapres Classifications: cardiovascular agent; central-acting antihypertensive; analgesic

Dosage & Route

Action

Indication Step 2 drug in stepped-care approach to treatment of hypertension, either alone or with diuretic or other antihypertensive agents. Epidural administration as adjunct therapy for severe pain.

Adverse Effects CV: Hypotension (epidural), postural hypotension (mild), peripheral edema, ECG changes, tachycardia, bradycardia, flushing, rapid increase in BP with abrupt withdrawal. GI: Dry mouth, constipation, abdominal pain, pseudo-obstruction of large bowel, altered taste, nausea, vomiting, hepatitis, hyperbilirubinemia, weight gain (sodium retention). CNS: Drowsiness, sedation, dizziness, headache, fatigue, weakness, sluggishness, dyspnea, vivid dreams, nightmares, insomnia, behavior changes, agitation, hallucination, nervousness, restlessness, anxiety, mental depression. Skin: Rash, pruritus, thinning of hair, exacerbation of psoriasis; with transdermal patch: hyperpigmentation, recurrent herpes simplex, skin irritation, contact dermatitis, mild erythema. Special Senses: Dry eyes. Urogenital: Impotence, loss of libido.

Contraindication Pregnancy (category C), lactation. Use of clonidine patch in polyarteritis nodosa, scleroderma, SLE

Nursing Responsibility

PO 75 mcg 1 tab SL Prn for BP >140


Centrally acting antiadrenergic derivative. Stimulates alpha2-adrenergic receptors in CNS to inhibit sympathetic vasomotor centers. Central actions reduce plasma concentrations of norepinephrine. It decreases systolic and diastolic BP and heart rate. Orthostatic effects tend to be mild and occur infrequently. Also inhibits renin release from kidneys.

Assessment & Drug Effects

Monitor BP closely. Determine positional changes (supine, sitting, standing). With epidural administration, frequently monitor BP and HR. Hypotension is a common side effect that may require intervention. Monitor BP closely whenever a drug is added to or withdrawn from therapeutic regimen. Monitor I&O during period of dosage adjustment. Report change in I&O ratio or change in voiding pattern. Determine weight daily. Patients not receiving a concomitant diuretic agent may gain weight, particularly during first 3 or 4 d of therapy, because of marked sodium and water retention. Supervise closely patients with history of mental depression, as they may be subject to further depressive episodes.

You might also like